1. Alternative dosing regimens for atezolizumab: right dose, wrong frequency

   • Daniel A. Goldstein
   • Mark J. Ratain

   Editorial 19 October 2019 Pages: 1153 - 1155

2. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs

   • Vinay Sharma
   • Sonu Kumar Gupta
   • Malkhey Verma

   Review Article 04 September 2019 Pages: 1157 - 1166

   

3. A reliable method to determine which candidate chemotherapeutic drugs effectively inhibit tumor growth in patient-derived xenografts (PDX) in single mouse trials

   • Derek Gordon
   • David E. Axelrod

   Original Article 12 September 2019 Pages: 1167 - 1178

   

4. A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics

   • Floor J. E. Lubberman
   • Guillemette E. Benoist
   • Nielka P. van Erp

   Original Article Open access 12 September 2019 Pages: 1179 - 1185

   

5. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate

   • Meng Gao
   • Dongjian Zhang
   • Feng Wang

   Original Article 13 September 2019 Pages: 1187 - 1194

   

6. Skin platinum deposition in colorectal cancer patients following oxaliplatin-based therapy

   • Yanshuo Cao
   • Qing Chang
   • Eric X. Chen

   Original Article 13 September 2019 Pages: 1195 - 1200

   

7. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial

   • Thehang Luu
   • Paul Frankel
   • Edward M. Newman

   Original Article 14 September 2019 Pages: 1201 - 1208

   

8. Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway

   • Yanshan Zhang
   • Weizuo Chen
   • Chao Li

   Original Article 16 September 2019 Pages: 1209 - 1218

   

9. Endothelial nitric oxide synthase c.-813C>T predicts for proteinuria in metastatic breast cancer patients treated with bevacizumab-based chemotherapy

   • Stefania Crucitta
   • Giuliana Restante
   • Romano Danesi

   Original Article 16 September 2019 Pages: 1219 - 1227

   

10. ABCC11 gene polymorphism as a potential predictive biomarker for an oral 5-fluorouracil derivative drug S-1 treatment in non-small cell lung cancer

    • Takehiro Uemura
    • Tetsuya Oguri
    • Akio Niimi

    Original Article 17 September 2019 Pages: 1229 - 1239

    

11. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer

    • Yuliang Sun
    • Xiaoqian Lin
    • Brian R. Leyland-Jones

    Original Article 20 September 2019 Pages: 1241 - 1256

    

12. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

    • Kari M. Morrissey
    • Mathilde Marchand
    • René Bruno

    Original Article Open access 21 September 2019 Pages: 1257 - 1267

    

13. JOIN trial: treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage II/III colon cancer

    • Takayuki Yoshino
    • Masahito Kotaka
    • Atsushi Ohtsu

    Original Article Open access 23 September 2019 Pages: 1269 - 1277

    

14. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells

    • Wei Yang
    • Sihui Zhao
    • Rong Zeng

    Original Article 23 September 2019 Pages: 1279 - 1288

    

15. Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies

    • Leonard J. Appleman
    • Jan H. Beumer
    • Suresh S. Ramalingam

    Original Article 23 September 2019 Pages: 1289 - 1301

    

16. NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells

    • Ling Liu
    • Jingjing Chen
    • Shuying Wang

    Original Article 25 September 2019 Pages: 1303 - 1314

    

17. Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study

    • Rasoul Irajirad
    • Amirhossein Ahmadi
    • Ali Shakeri-Zadeh

    Original Article 26 September 2019 Pages: 1315 - 1321

    

18. A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors

    • Mohammad Wasif Saif
    • Shrikar Rajagopal
    • Robert Martell

    Original Article 03 October 2019 Pages: 1323 - 1331

    

19. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1

    • Caner Turan
    • Mehmet Kantar
    • Tayfun Kirazlı

    Original Article 04 October 2019 Pages: 1333 - 1338

20. Population pharmacokinetic analysis of high-dose methotrexate in pediatric and adult oncology patients

    • Sonoko Kawakatsu
    • Mina Nikanjam
    • Edmund V. Capparelli

    Original Article 04 October 2019 Pages: 1339 - 1348

    

21. Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial

    • Ya Zheng
    • Jie Zhu
    • Hong Sun

    Clinical Trial Report 18 October 2019 Pages: 1349 - 1357

    

22. Prevalence of the DPYD variant (Y186C) in Brazilian individuals of African ancestry

    • Geraldo Felício Cunha-Junior
    • Luciana Bastos-Rodrigues
    • Luiz Gonzaga Coelho

    Short Communication 22 October 2019 Pages: 1359 - 1363

23. Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

    • Fernando Rivera
    • C. Romero
    • C. López

    Correction Open access 05 October 2019 Pages: 1365 - 1365